RIGEL PHARMACEUTICALS INC: insider trades · United States · SEC (Form 4)

About RIGEL PHARMACEUTICALS INC

Rigel Pharmaceuticals, Inc. (ticker: RIGL) is a Nasdaq-listed biotechnology company in the United States, with its principal executive offices in South San Francisco, California. Founded in the late 1990s, Rigel was built around small-molecule drug discovery and development, initially focused on signaling pathways relevant to immune, inflammatory, hematologic, and oncologic diseases. Over time, the company has evolved from a pure R&D platform into a commercial-stage biotech with recurring product revenue plus collaboration income. ([rigel.com](https://www.rigel.com/investors/sec-filings/all-sec-filings/content/0001034842-26-000015/0001034842-26-000015.pdf)) Rigel’s current business is anchored by three marketed products and one active development candidate. TAVALISSE (fostamatinib) is approved in the U.S. for adult patients with chronic immune thrombocytopenia who have had an insufficient response to a prior treatment, and it also has international partnering activity. REZLIDHIA (olutasidenib) is approved for relapsed or refractory IDH1-mutated acute myeloid leukemia and remains a key hematology-oncology asset. GAVRETO (pralsetinib), acquired from Blueprint in 2024, is a once-daily RET inhibitor used in certain RET fusion-positive non-small cell lung cancer and advanced thyroid cancer settings. Beyond commercialization, Rigel is advancing R289, an investigational hematology program currently in dose-expansion work in lower-risk myelodysplastic syndromes. ([rigel.com](https://www.rigel.com/investors/sec-filings/all-sec-filings/content/0001034842-26-000015/0001034842-26-000015.pdf)) From a market-positioning standpoint, Rigel is a niche player rather than a broad-based pharma company. Its strategy is to compete in targeted rare and specialty disease segments where biomarker-driven medicines can command clinical differentiation, while leveraging a relatively lean commercial footprint. The company’s SEC filings emphasize that its products compete against established therapies and emerging pipeline assets, particularly in ITP, AML, and RET-altered cancers. In practical terms, that means Rigel’s investment case depends on maintaining product uptake, defending pricing and access, and continuing to generate supportive clinical evidence. ([rigel.com](https://www.rigel.com/investors/sec-filings/all-sec-filings/content/0001034842-26-000015/0001034842-26-000015.pdf)) Recent developments have been meaningful. Rigel reported approximately $294.3 million of total revenue in 2025, including $232.0 million of net product sales, and guided to roughly $275 million to $290 million of total revenue for 2026 with expected full-year profitability. The company also published final five-year data for REZLIDHIA in 2025, announced progress on R289 in March 2026, and highlighted a U.S. regulatory update for GAVRETO at the end of 2025. For international equity investors, RIGL is best viewed as a U.S.-listed commercial biotech with improving financial scale, a focused hematology/oncology franchise, and material event-driven upside and risk tied to clinical and regulatory execution. ([rigel.com](https://www.rigel.com/investors/sec-filings/all-sec-filings/content/0001034842-26-000016/0001034842-26-000016.pdf))